Celsion Corporation (Nasdaq: CLSN) announced today that an abstract on its Phase I/II DIGNITY trial of ThermoDox® in Recurrent Chest Wall (RCW) Breast Cancer has been accepted for a poster session at the 2010 Breast Cancer Symposium. The abstract will provide updated clinical results, as well as the rationale and design of the DIGNITY study, which is evaluating ThermoDox in combination with microwave hyperthermia in women with RCW Breast Cancer. The meeting will be held October 1 - 3, 2010 at the Gaylord National Hotel in Suburban Washington, DC.
The abstract, titled "Phase I/II study evaluating the maximum tolerated dose, pharmacokinetics, safety, and efficacy of hyperthermia and lyso-thermosensitive liposomal doxorubicin in patients with breast cancer recurrence at the chest wall," is authored by Brigid O'Connor, M.D., Ph.D., lead clinical investigator from the Rhode Island Hospital in Providence, RI.
"We are delighted to present updated clinical data for the DIGNITY study at this prominent conference. The ASCO community has been very supportive of our ThermoDox clinical trials," said Michael H. Tardugno, Celsion's President and Chief Executive Officer. "Addressing this unmet medical need is a very high priority for our company, as well as our investigators."
Dr. Nicholas Borys, Chief Medical Officer at Celsion Corporation commented, "The breast cancer community has demonstrated an increase in interest in the DIGNITY study. In 2010, three DIGNITY abstracts will have been presented at major cancer meetings. The other abstracts have been published at the June 2010 ASCO (American Society of Clinical Oncology) meeting in Chicago and the upcoming ASTRO (American Society for Radiation Oncology) meeting in October. We are also gratified to report that the last cohort of the DIGNITY study enrolled very rapidly. We hope these updated clinical results will increase awareness among oncologists and their patients."
Principal investigator Dr. O'Connor commented, "Although treatment using heat sensitive liposomal doxorubicin with microwave hyperthermia (heat) is investigational at this time, we are encouraged that this approach may provide a promising outcome for breast cancer patients with painful loco-regional recurrence on the chest wall. Rapid evaluation of ThermoDox is warranted as we search for ways to provide patients with better treatment options for this devastating disease."
Study shows cannabis as a genotoxic substance with cancer risks